Clinical Trial Update: A Study of Sintilimab Compared With Docetaxel or Pemetrexed as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer After Failure With Platinum-Containing Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sintilimab vs docetaxel or pemetrexed as second-line therapy for stage IV nonsquamous non-small cell lung cancer after platinum failure…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Pemetrexed (pemetrexed)
• Sintilimab (sintilimab)

Snippet

Sponsor: Xin-Hua Xu | Conditions: Nonsquamous Non-Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN